Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes  INDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT ph ...